Nomura Holdings’s Cytokinetics CYTK Stock Holding History

Nomura Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-259,000	Closed	-$17.1M	–	1857
2026 Q1	$17.1M	Buy	259,000 +4,800	+2%	+$305K	0.05%	288
2025 Q4	$16.2M	Buy	254,200 +5,000	+2%	+$311K	0.02%	375
2025 Q3	$13.7M	Buy	249,200 +194,700	+357%	+$8.02M	0.02%	415
2025 Q2	$1.8M	Sell	54,500 -3,000	-5%	-$104K	﹤0.01%	862
2025 Q1	$2.31M	Sell	57,500 -463,000	-89%	-$21.3M	﹤0.01%	1004
2024 Q4	$24.5M	Buy	520,500 +400,500	+334%	+$20.8M	0.03%	271
2024 Q3	$6.34M	Sell	120,000 -50,000	-29%	-$2.79M	0.01%	575
2024 Q2	$9.21M	Buy	170,000 +50,000	+42%	+$3.02M	0.02%	473
2024 Q1	$8.41M	Buy	120,000 +37,600	+46%	+$2.91M	0.02%	493
2023 Q4	$6.88M	Buy	+82,400	New	+$2.98M	0.02%	567
2014 Q2	–	Sell	-22,500	Closed	-$213K	–	2790
2014 Q1	$213K	Buy	+22,500	New	+$204K	﹤0.01%	2299

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's CYTK Position: Q2 2026 in Review

Nomura Holdings increased its Cytokinetics (CYTK) stake by 723% in Q2 2026, buying an estimated $2.14M and bringing the position to 34,000 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #972.

Nomura Holdings first reported a position in CYTK in Q1 2014 and has held it in 13 quarters since. The position peaked at $7.76M in Q3 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Nomura Holdings held 34,000 shares of Cytokinetics worth $2.9M as of Q2 2026.
Nomura Holdings bought 29,870 Cytokinetics shares in Q2 2026, an estimated $2.14M.
Cytokinetics made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #972 holding.
Nomura Holdings first reported a position in Cytokinetics in Q1 2014 and has held it in 13 quarters since.
Nomura Holdings's Cytokinetics position peaked at $7.76M in Q3 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.